Is this cannabis-based alternative to opioid painkillers the key to treating chronic pain?
Is this cannabis-based alternative to opioid painkillers the key to treating chronic pain? - It’s high time for a ...
Scientists Discover Natural Pain Reliever in Cannabis That May Rival Opioids
The study, which was published in the journal Pharmacological Reports, analyzed the impact of four terpenes that are found in ...
Physician's Weekly1d
Addressing Acute Pain & Related Challenges: Will Recent FDA Approval of a Novel Non-Opioid Analgesic Be a Game Changer?
FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...
Palliative care patients face added stress and extra costs amid pain medicine shortages
Doctors often prescribe strong medications to relieve pain, distress and discomfort in palliative care, but many of these ...
FDA approves first non-opioid pain treatment in two decades, providing new hope
Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...
Pharmaceutical Technology on MSN10d
Latigo secures $150m for non-opioid pain treatment development
Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its ...
EurekAlert!1d
Removing barriers to high-quality opioid use disorder care
Nurse-scientist hopes to empower primary care nurse practitioners to play a crucial role in improving access to ...
Managed Healthcare Executive3d
Is Journavx a Step Forward In Pain Management or a Repeat of Past Mistakes?
Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...
2 Minute Medicine3d
Evidence gap for acute pain outcomes in opioid use disorder
In this systematic review, evidence for the efficacy of acute pain interventions on individuals with opioid use disorder was ...
Fierce Biotech10d
Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic
Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...
Yahoo Finance10d
Latigo secures $150m for non-opioid pain treatment development
The company has recently shared encouraging Phase I outcomes for its orally administered lead candidate, LTG-001, for non-opioid pain relief. This selective Na v 1.8 inhibitor is aimed at ...